First, although patients who respond to anti-PD1 showed significant tumour reduction and improved progression-free survival, the response rate is relatively low, e.g. about 30–40% in advanced melanoma and 20% in NSCLC [10]. This evidence concerns the gene PDCD1 and neoplasm.